Display options
Cite
Wenzel L, Osann K, McKinney C, et al. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. J Natl Cancer Inst. 2021;113(10):1369-1378doi: 10.1093/jnci/djab034.
Wenzel, L., Osann, K., McKinney, C., Cella, D., Fulci, G., Scroggins, M. J., Lankes, H. A., Wang, V., Nephew, K. P., Maxwell, G. L., Mok, S. C., Conrads, T. P., Miller, A., Mannel, R. S., Gray, H. J., Hanjani, P., Huh, W. K., Spirtos, N., Leitao, M. M., Glaser, G., Sharma, S. K., Santin, A. D., Sperduto, P., Lele, S. B., Burger, R. A., Monk, B. J., & Birrer, M. (2021). Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. Journal of the National Cancer Institute, 113(10), 1369-1378. https://doi.org/10.1093/jnci/djab034
Wenzel, Lari, et al. "Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival." Journal of the National Cancer Institute vol. 113,10 (2021): 1369-1378. doi: https://doi.org/10.1093/jnci/djab034
Wenzel L, Osann K, McKinney C, Cella D, Fulci G, Scroggins MJ, Lankes HA, Wang V, Nephew KP, Maxwell GL, Mok SC, Conrads TP, Miller A, Mannel RS, Gray HJ, Hanjani P, Huh WK, Spirtos N, Leitao MM, Glaser G, Sharma SK, Santin AD, Sperduto P, Lele SB, Burger RA, Monk BJ, Birrer M. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. J Natl Cancer Inst. 2021 Oct 01;113(10):1369-1378. doi: 10.1093/jnci/djab034. PMID: 33729494; PMCID: PMC8486331.
Copy Download .nbib Format: NLM
Share it on

J Natl Cancer Inst. 2021 Oct 01;113(10):1369-1378. doi: 10.1093/jnci/djab034.

Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival.

Journal of the National Cancer Institute

Lari Wenzel, Kathryn Osann, Chelsea McKinney, David Cella, Giulia Fulci, Mary J Scroggins, Heather A Lankes, Victoria Wang, Kenneth P Nephew, George L Maxwell, Samuel C Mok, Thomas P Conrads, Austin Miller, Robert S Mannel, Heidi J Gray, Parviz Hanjani, Warner K Huh, Nick Spirtos, Mario M Leitao, Gretchen Glaser, Sudarshan K Sharma, Alessandro D Santin, Paul Sperduto, Shashikant B Lele, Robert A Burger, Bradley J Monk, Michael Birrer

Affiliations

  1. Department of Medicine and Program in Public Health, University of California, Irvine, CA, USA.
  2. Department of Medical Social Sciences, Northwestern University Health System, Chicago, IL, USA.
  3. GlaxoSmithKline; Waltham, MA, USA.
  4. International Gynecology Cancer Society, Austin, TX, USA.
  5. NRG Oncology, Philadelphia, PA, USA.
  6. Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
  7. Medical Sciences Program, Indiana University School of Medicine-Bloomington, Bloomington, IN, USA.
  8. Women's Health Integrated Research Center at Inova Health System, Women's Service Line, Inova Health System, Falls Church, VA, USA.
  9. Department of Gynecological Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  10. Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  11. Stephenson Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK, USA.
  12. Gynecologic Oncology, University of Washington Medical Center, Seattle, WA, USA.
  13. Gynecologic Oncology, Abington-Jefferson Health, Abington, PA, USA.
  14. University of Alabama Highlands, Birmingham, AL, USA.
  15. Women's Cancer Center of Nevada, Las Vegas, NV, USA.
  16. Memorial Sloan Kettering Cancer and Weill Cornell Medical Center, New York, NY, USA.
  17. Gynecologic Oncology, Mayo Clinic, Owatonna, MN, USA.
  18. AMITA Health Physicians, Hinsdale, IL, USA.
  19. Department of Obstetrics, Gynecology and Reproductive Services, Yale University School of Medicine, New Haven, CT, USA.
  20. Minneapolis Radiation Oncology and Metro-Minnesota Community Oncology Research Consortium, St. Louis Park, MN, USA.
  21. Genentech, Oceanside, CA, USA.
  22. Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix, AZ, USA.
  23. Winthrop P. Rockefeller Cancer Institute University of Arkansas for Medical Sciences, Little Rock, AR, USA.

PMID: 33729494 PMCID: PMC8486331 DOI: 10.1093/jnci/djab034

Abstract

BACKGROUND: There is a critical need to identify patient characteristics associated with long-term ovarian cancer survival.

METHODS: Quality of life (QOL), measured by the Functional Assessment of Cancer Therapy-Ovarian-Trial Outcome Index (FACT-O-TOI), including physical, functional, and ovarian-specific subscales, was compared between long-term survivors (LTS) (8+ years) and short-term survivors (STS) (<5 years) of GOG 218 at baseline; before cycles 4, 7, 13, 21; and 6 months post-treatment using linear and longitudinal mixed models adjusted for covariates. Adverse events (AEs) were compared between survivor groups at each assessment using generalized linear models. All P values are 2-sided.

RESULTS: QOL differed statistically significantly between STS (N = 1115) and LTS (N = 260) (P < .001). Baseline FACT-O-TOI and FACT-O-TOI change were independently associated with long-term survival (odds ratio = 1.05, 95% confidence interval = 1.03 to 1.06 and odds ratio = 1.06, 95% confidence interval = 1.05 to 1.07, respectively). A 7-point increase in baseline QOL was associated with a 38.0% increase in probability of LTS, and a 9-point increase in QOL change was associated with a 67.0% increase in odds for LTS. QOL decreased statistically significantly with increasing AE quartiles (cycle 4 quartiles: 0-5 vs 6-8 vs 9-11 vs ≥12 AEs, P = .01; cycle 21 quartiles: 0-2 vs 3 vs 4-5 vs ≥6 AEs, P = .001). Further, LTS reported statistically significantly better QOL compared with STS (P = .03 and P = .01, cycles 4 and 21, respectively), with similar findings across higher AE grades.

CONCLUSIONS: Baseline and longitudinal QOL change scores distinguished LTS vs STS and are robust prognosticators for long-term survival. Results have trial design and supportive care implications, providing meaningful prognostic value in this understudied population.

© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please email: [email protected].

References

  1. J Clin Oncol. 2001 Mar 15;19(6):1809-17 - PubMed
  2. Cancer. 2014 Jan 15;120(2):302-11 - PubMed
  3. Eur J Cancer. 2018 Jan;88:31-37 - PubMed
  4. J Natl Cancer Inst. 2020 Dec 14;112(12):1266-1274 - PubMed
  5. Br J Cancer. 2014 May 13;110(10):2427-33 - PubMed
  6. JAMA Oncol. 2017 Aug 1;3(8):1043-1050 - PubMed
  7. Cancer. 2018 Aug;124(16):3409-3416 - PubMed
  8. Clin Cancer Res. 2016 Apr 1;22(7):1553-8 - PubMed
  9. Med Care. 2003 May;41(5):582-92 - PubMed
  10. Health Qual Life Outcomes. 2010 Sep 21;8:104 - PubMed
  11. Support Care Cancer. 2012 Oct;20(10):2553-7 - PubMed
  12. Gynecol Oncol. 2012 Mar;124(3):379-82 - PubMed
  13. Gynecol Oncol. 2008 Jul;110(1):60-4 - PubMed
  14. Gynecol Oncol. 2017 Oct;147(1):98-103 - PubMed
  15. Qual Life Res. 2005 Mar;14(2):285-95 - PubMed
  16. Gynecol Oncol. 2008 Jan;108(1):100-5 - PubMed
  17. Gynecol Oncol. 2016 Dec;143(3):611-616 - PubMed
  18. J Pain Symptom Manage. 2015 Sep;50(3):321-7 - PubMed
  19. Lancet Oncol. 2009 Sep;10(9):865-71 - PubMed
  20. J Clin Oncol. 2008 Mar 10;26(8):1355-63 - PubMed
  21. J Natl Cancer Inst. 2009 Dec 2;101(23):1624-32 - PubMed
  22. Oncologist. 2016 Mar;21(3):354-76 - PubMed
  23. Support Care Cancer. 2008 Jan;16(1):47-56 - PubMed
  24. J Clin Oncol. 2016 Feb 20;34(6):557-65 - PubMed
  25. Qual Life Res. 1997 Mar;6(2):151-8 - PubMed
  26. Int J Cancer. 2011 Jun 15;128(12):3005-11 - PubMed
  27. Lancet Oncol. 2015 Nov;16(15):1445-1446 - PubMed
  28. Clin Cancer Res. 2016 Dec 1;22(23):5909-5914 - PubMed
  29. N Engl J Med. 2011 Dec 29;365(26):2473-83 - PubMed
  30. Expert Rev Anticancer Ther. 2018 Oct;18(sup1):3-7 - PubMed
  31. Lancet Oncol. 2018 Aug;19(8):1126-1134 - PubMed
  32. J Clin Oncol. 2005 Aug 20;23(24):5605-12 - PubMed
  33. Gynecol Oncol. 2014 Jul;134(1):60-7 - PubMed
  34. J Clin Epidemiol. 2011 May;64(5):507-16 - PubMed
  35. Ann Oncol. 2017 Aug 1;28(8):1849-1855 - PubMed
  36. Lancet Oncol. 2006 Nov;7(11):903-9 - PubMed
  37. Gynecol Oncol. 2017 Jul;146(1):101-108 - PubMed
  38. Support Care Cancer. 2019 Feb;27(2):531-538 - PubMed
  39. J Clin Oncol. 2012 Aug 10;30(23):2885-90 - PubMed
  40. Obstet Gynecol. 2015 Sep;126(3):491-497 - PubMed
  41. J Clin Oncol. 2019 Sep 10;37(26):2317-2328 - PubMed
  42. Gynecol Oncol. 2013 Mar;128(3):573-8 - PubMed

Publication Types

Grant support